The Prolaris Test is a genomic test for prostate cancer combining clinical and pathological features with a personalized tumor aggressiveness score to help determine if a patient can safely stay on active surveillance or should pursue treatment.
Many men eligible for active surveillance may safely avoid treatment for at least 10 years.1 That means more time living life, not managing treatment and side-effects.
The Prolaris Test provides clear answers to help support discussions with your low- and intermediate-risk patients that are considering active surveillance.2,3
Improving the patient experience through genomics
Request a consultation or receive more information about integrating the Prolaris Test into your clinical workflow.
You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.
Contact Information
The Prolaris Test helps inform providers on potential changes to treatment plans.
In real-world clinical studies, the Prolaris Test influenced treatment decision changes in up to 65% of cases, helping clinicians to shift between active surveillance and definitive treatment based on individual risk.4,5
In a recent study, patients recommended for active surveillance by the Prolaris Test were twice as likely to choose it and had 50% higher 3-year durability compared to those recommended for definitive treatment.6
of patients tested with the Prolaris Test had a change in their treatment plan4,5
The Prolaris Test is two times more prognostic than PSA/Gleason alone9
The Prolaris Test combines clinical-pathological features with an independent molecular score measuring the expression of 31 Cell Cycle Proliferation (CCP) genes, CCP), making it two times more prognostic than clinical features alone.7-9
The Prolaris Test is the only test with two clinically validated thresholds — one for identifying patients suitable for active surveillance, and another for guiding single-modal vs multi-modal therapy decisions such as adding androgen deprivation therapy (ADT) to radiation therapy (RT).2,10
Identify active surveillance (AS) patients at time of biopsy
Because the Prolaris Test was developed and validated on untreated men,5 AS conversations with the untreated patient in front of you are more relevant and informed.5
The Prolaris Test outperforms all other biomarkers in identifying the right patients for active surveillance in both low and intermediate risk populations.5
In the Prolaris Test validation study, NO patient below the AS threshold died of prostate cancer.5
The Prolaris Test best aligns with patients studied in ProtecT, the largest randomized trial of AS or treatment in screen-detected localized prostate cancer.6
Identify the patients who need definitive treatment and at what intensity
The Prolaris Test shows that those patients who fall below the multi-modal threshold do not benefit from intensifying treatment11
Establishing the multi-modal threshold
The Prolaris Test threshold was developed on approximately 1,500 intermediate and high-risk patients from two separate cohorts.
Validating patients prior to a multi-modal treatment
Patients were separated by those who received single-modal therapy versus those with multiple modes of treatment.
Guide the androgen deprivation therapy (ADT) conversation
Multiple groups with ADT variations evaluated for metastasis
The Multi-modal threshold was developed and double-validated across all outcomes to predict the risk of metastasis and determine which patients can appropriately forego ADT.11,12
At or below the multi-modal threshold(8.8% metastasis risk)
The Prolaris Test gives your patients personalized, shareable guidance and a simple “number-needed-to-treat” value.
Is ADT right for this patient?
Myriad Oncology™ helps customize your ordering process to meet your practice’s unique needs. With a physician-driven, conditional ordering model, Prolaris testing can be initiated directly from the pathology lab — so you get critical results faster, right when treatment decisions are being made.
The beauty of conditional ordering? You stay in control — you decide which patients to test, and Myriad builds a workflow to support that.
Access detailed ordering instructions, specimen handling guidelines, and pathology resources to streamline every step of the testing process.
Imagine having a tool to clearly explain risks, thresholds, and treatment implications to your patients, step-by-step. The Prolaris Test results are designed with patients and providers in mind to quickly answer pressing clinical questions, improving confidence in selecting the most appropriate management option.
Explore more tests and resources to support your prostate cancer patients.
This casual, yet educational, podcast is committed to keeping you informed on all things urology.
Hear from fellow clinicians on how the Prolaris Test has changed the way they manage prostate cancer care.
References:
©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, Prolaris, MyRisk, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.